| Methods of treating iga nephropathy with an april binding antibody |
2022-11-17 |
2023-1-01 |
|
| Substituted pyrazolyl compounds and methods of use thereof |
2022-11-15 |
2023-1-01 |
|
| Methods of treating diabetic kidney disease |
2022-10-11 |
2022-12-01 |
|
| Methods of treating iga nephropathy with atrasentan |
2022-6-14 |
2022-8-01 |
|
| Substituted indole compounds and methods of use thereof |
2022-6-03 |
2022-12-08 |
|
| Methods of reducing disease flares |
2022-5-27 |
2022-9-29 |
|
| Pyridinyl indole compounds and methods of use thereof |
2022-4-06 |
2022-10-27 |
|
| Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use … |
2021-9-23 |
2022-3-31 |
|
| Substituted pyrazolyl compounds and methods of use thereof |
2021-5-17 |
2023-3-29 |
|
| Methods and compositions for treatment of cancer and infectious diseases |
2020-10-28 |
2021-5-06 |
|
| Imidazopyridazinone compounds and uses thereof |
2019-12-10 |
2020-6-11 |
|
| Dc-sign antibody conjugates comprising sting agonists |
2019-10-30 |
2021-9-08 |
|
| Compositions and methods for activating “stimulator of interferon gene”13 … |
2019-10-21 |
2021-6-22 |
2021-6-22 |
| Triazine Compounds and Uses Thereof |
2019-6-14 |
2021-8-12 |
|
| Combination therapy for the treatment of cancer |
2019-2-01 |
2022-7-07 |
|
| Pyrazolopyrimidinone compounds and uses thereof |
2018-9-14 |
2020-8-11 |
2020-8-11 |
| Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof |
2018-4-26 |
2021-4-13 |
2021-4-13 |
| Antibody conjugates comprising sting agonist |
2018-4-26 |
2020-3-04 |
|
| Compositions containing cyclic purine dinucleotides with defined … |
2018-4-25 |
2020-6-03 |
2020-6-03 |
| Signal peptide fusion partners facilitating expression of Listeria antigen … |
2018-4-06 |
2020-3-25 |
2020-3-25 |
| Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
2017-7-01 |
2021-8-24 |
2021-8-24 |
| Compositions and methods for activating "stimulator of interferon gene"- … |
2016-10-28 |
2019-2-28 |
|
| Epithelial growth factor receptor mutant III-mesoterin fusion and method of … |
2016-4-12 |
2020-11-11 |
2020-11-11 |
| Methods and compositions for using Listeria in cancer adjuvant pharmacotherapy |
2016-4-01 |
2017-12-13 |
2017-12-13 |
| Methods and compositions using Listeria for enhancing immunogenicity by prime … |
2015-11-25 |
2018-1-30 |
2018-1-30 |
| Compositions and methods for inhibiting "stimulating factor of interferon gene" … |
2014-5-18 |
2016-10-13 |
|
| Engineered Listeria and methods of use thereof |
2013-11-12 |
2017-9-19 |
2017-9-19 |
| Conditionally attenuated bacterial species and their preparation and use |
2013-11-06 |
2015-12-07 |
|
| Compositions and methods for cancer immunotherapy |
2013-6-07 |
2018-1-10 |
2018-1-10 |
| Listeria attenuated for entry into non-phagocytic cells, vaccines comprising … |
2010-3-29 |
2011-8-18 |
|
| Modified free-living microbes, vaccine compositions and methods of use thereof |
2006-8-11 |
2011-4-19 |
2011-4-19 |
| Recombinant nucleic acid molecules, expression cassettes, and bacteria, and … |
2004-12-23 |
2005-11-10 |
|
| Modified free-living microbes, vaccine compositions and methods of use thereof |
2004-2-06 |
2004-10-07 |
|